Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

August 9, 2017August 9, 2017

Physical Activity May Predict Mortality Risk Among IPF Patients, German Researchers Say

Idiopathic Pulmonary Fibrosis, News

Physical activity may accurately predict mortality among idiopathic pulmonary fibrosis (IPF) patients, finds a German study, “Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis,” that appeared in the journal BMC ... Read more

August 1, 2017August 1, 2017

Inventiva to Release Novel Data on Anti-fibrotic Product, IVA337, at Scleroderma Workshop

News

French pharmaceutical firm Inventiva will present novel data on its new anti-fibrotic product, IVA337, during the 15th International Workshop on Scleroderma Research, to be held Aug. 5-9 at the University of Pittsburgh. ... Read more

July 31, 2017July 31, 2017

Revefenacin May Be Potential Treatment for COPD Patients, Phase 3 Clinical Trial Shows

COPD, News

Treatment with revefenacin (TD-4208) has shown promise in a Phase 3 clinical trial (NCT02518139) with chronic obstructive pulmonary disease (COPD) patients, said Theravance Biopharma and Mylan. Revefenacin is an investigational long-acting ... Read more

July 27, 2017July 27, 2017

Survey Seeks to Better Understand Psychological Burden Associated with IPF

Idiopathic Pulmonary Fibrosis, News

Patients with idiopathic pulmonary fibrosis (IPF) frequently experience anxiety, fear, uncertainty, hopelessness, and limitations in daily activities, according to a global survey conducted by the pharmaceutical company Boehringer Ingelheim. “We know ... Read more

July 14, 2017July 14, 2017

Researchers Identify a Type of Immune Cells that Contribute to Lung Fibrosis

Idiopathic Pulmonary Fibrosis, News

Certain immune cells, called monocyte-derived alveolar macrophages, may contribute to lung inflammation and fibrosis, according to the results of a new study. Researchers believe that therapies targeting these monocyte-derived macrophages may ... Read more

June 30, 2017June 30, 2017

New Esbriet Tablets for IPF Treatment Now Available in Europe

Idiopathic Pulmonary Fibrosis, News

The European Commission has approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Esbriet, developed by Roche, is an oral antifibrotic medication approved ... Read more

June 27, 2017June 27, 2017

FDA Approves Tafinlar/Mekinist Combo to Treat Specific Type of Lung Cancer

Lung Cancer, News

The U.S. Food and Drug Administration (FDA) approved the combination therapy Tafinlar (dabrafenib) and Mekinist (trametinib) as a treatment for patients with metastatic non-small cell lung cancer (NSCLC) carrying specific ... Read more

June 15, 2017June 15, 2017

Pulmatrix Strikes Licensing Deal to Gain Access to RespiVert’s Lung Disease Treatments

Idiopathic Pulmonary Fibrosis, News

Pulmatrix has signed a licensing agreement with RespiVert, a subsidiary of Janssen Biotech, to gain access to RespiVert’s portfolio of kinase inhibitors for treating lung diseases. Kinase inhibitors act by blocking ... Read more

May 31, 2017May 31, 2017

Pulmonary Fibrosis Foundation Says U.S. Database Now Has 1,000 PF Patients, Half of 2017 Enrollment Target

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) has announced that 1,000 Americans with pulmonary fibrosis (PF) have enrolled in its Patient Registry. The goal is to enroll another 1,000 patients by the end of 2017 ... Read more

May 26, 2017May 26, 2017

Ofev Doubles the Chance of Improving or Stabilizing IPF, Studies Find

Idiopathic Pulmonary Fibrosis, News

Idiopathic pulmonary fibrosis (IPF) patients treated with Ofev (nintedanib) are twice as likely to improve or see their disease stabilize than untreated patients, according to a pool of data from ... Read more